Abstract 486P
Background
Our research group has previously established the cost-effectiveness (CE) of lung cancer screening (LCS) with low-dose computed tomography (LDCT) for both high-risk smokers and non-smokers in Hong Kong (HK). Integrating LCS into the existing infrastructure in HK however requires systematic and rigorous design and execution. Thus, we undertook sensitivity and scenario analyses for LCS beyond fundamental base-case examination. The aim was to explore balance between clinical efficacy and resource optimization for LCS implementation in HK.
Methods
A CE analysis was conducted using decision tree and state-transition Markov model to simulate identification, diagnosis, and treatments for a high-risk population defined by the NELSON study and the TALENT study. One-way sensitivity analysis (OSA) was conducted with ±20% variation of the base-case parameter values. Scenario analyses were undertaken to explore the CE of LCS with varying costs. The incremental cost-effectiveness (ICER) was estimated as costs per quality-adjusted life-year (QALY).
Results
OSA showed that LDCT costs were the main driver for the ICER of LCS targeting heavy smokers, 20% increase in LDCT costs led to an ICER of USD 18,002 (22% higher than base-case ICER). Meanwhile, 20% increase in the treatments costs for stage I LC led to an ICER of 10,844 (7% higher than base-case ICER) for the LCS targeting high-risk non-smokers. Scenario analyses additionally indicated that restraining costs for CT scan, diagnosis, and early-stage LC treatments would yield a reduction in ICER (Table). Table: 486P
Scenario analysis | Smoker | Non smokers | ||
ICER (USD) ∗ | Reduction in ICER ∗ | ICER (USD) | Reduction in ICER | |
Base-case analysis | $14,723 | NA. | $10,096 | NA. |
Cut down unit costs for low-dose CT scans (LDCT) - USD $ 191 | $12,070 | 18% | $9,520 | 6% |
Cut down unit costs for LDCT - USD $ 127 | $9,377 | 36% | $8,934 | 12% |
Cut down unit costs for LDCT - USD $ 64 | $6,684 | 55% | $8,349 | 17% |
Half diagnostic costs for stage I - USD $ 836 (per person) | $14,472 | 2% | $9,635 | 5% |
Half diagnostic costs for stage IV - USD $ 3,922 (per person) | $14,969 | -2% | $8,872 | 12% |
Half treatment costs for the ongoing phase for stage I patients (per 3 months) - USD $ 247 | $13,296 | 10% | $8,777 | 13% |
Half treatment costs for the ongoing phase for stage IV patients (per 3 months) - USD $ 417 | $14,974 | -2% | $10,145 | 0% |
Conclusions
Fiscal restraint on CT scanning and early-stage LC treatments expenditures are necessary to ensure feasible and sustainable LCS implementation in HK. Our findings provide important benchmarks for the HK Government’s consideration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca Hong Kong.
Disclosure
H.H.F. Loong: Financial Interests, Institutional, Invited Speaker: Boehringer Ingelheim, MSD; Financial Interests, Personal, Invited Speaker: Eli Lilly, Illumina, Bayer, Guardant Health; Financial Interests, Personal, Advisory Board: Novartis, Takeda. X. Pan: Financial Interests, Personal, Financially compensated role: i-DNA. All other authors have declared no conflicts of interest.
Resources from the same session
382P - Oral health disparities in privileged and underprivileged tribes of south India: A study of the prevalence of precancerous oral lesions
Presenter: Shanavas Palliyal
Session: Poster Display
Resources:
Abstract
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract